MRK · News · 20260820N
AI Vaccine Licensing Deal
Merck & Co., Inc. · 2026-08-20 · Importance 34 · Surprise 42 · In source text
Merck disclosed a significant stake in Evaxion A/S, an AI immunology company focused on computational vaccine discovery. Merck also in-licensed Evaxion’s AI-discovered vaccine candidate EVX-B3. The transaction provides a strategic link between Merck’s vaccine-development activities and AI-enabled immunology, while further preclinical progress and integration into Merck’s pipeline remain key uncertainties. The digest does not provide the investment amount, licensing economics, development timetable, or regulatory milestones.
Key facts
- Merck disclosed a significant stake in Evaxion A/S and decided to in-license Evaxion's AI-discovered vaccine candidate EVX-B3. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | realized | — | Merck disclosed a significant stake in Evaxion A/S and decided to in-license Evaxion's AI-discovered vaccine candidate EVX-B3. |
| revenue | positive | probable | — | Merck disclosed a significant stake in Evaxion A/S and decided to in-license Evaxion's AI-discovered vaccine candidate EVX-B3. |